Modality
Gene Therapy
MOA
CDK2i
Target
WRN
Pathway
PI3K/AKT
Alzheimer's
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
~Oct 2018
→ ~Jan 2020
Phase 2
~Apr 2020
→ ~Jul 2021
Phase 3
Oct 2021
→ Nov 2030
Phase 3Current
NCT08962142
2,993 pts·Alzheimer's
2021-10→2030-11·Completed
2,993 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-264.7y awayPh3 Readout· Alzheimer's
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Complet…
Catalysts
Ph3 Readout
2030-11-26 · 4.7y away
Alzheimer's
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08962142 | Phase 3 | Alzheimer's | Completed | 2993 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Mavuglumide | Bayer | Approved | GLP-1R |